Anti-tuberculosis vaccine BCG10

Anti-tuberculosis vaccine BCG10
Product Description

BCG 10 Anti-Tuberculosis Vaccine is used for protective vaccinations against tuberculosis. Catch-up (supplementary) vaccinations in subjects unvaccinated after birth should be performed as early as possible, no later than at 15 years of age. In case of BCG immunisation booster vaccine doses are not recommended. One dose (0.1 ml) contains 50 micrograms of semi-dry mass of BCG bacilli which corresponds to amount from 150 000 to 600 000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain. One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.

Read more Show less

Synthaverse S.A.

  • Country/Region:
    Poland
  • On CPHI since:
    2023
  • Certificates:
    1
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

Synthaverse S.A.

  • Country/Region:
    Poland
  • On CPHI since:
    2023
  • Certificates:
    1
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile

More Products from Synthaverse S.A. (2)

  • BCG10 anti-tuberculosis vaccine

    Product BCG10 anti-tuberculosis vaccine

    Freeze-dried powder of live attenuated BCG bacilli, the Brazilian Moreau substrain, for suspension for intradermal injection. 5 ampoules with powder and 5 ampoules with solvent, 1 ml each. 0.1 ml for one child, 1 ampoule – 10 vaccinations, 1 pack – 50 vaccinations
  • Distreptaza

    Product Distreptaza

    Supportive treatment of pelvic inflammatory disease (PID) – inflammatory diseases of the ovaries, fallopian tubes and endometrium. Adhesions after abdominal surgical procedures. Acute haemorrhoidal disease and chronic haemorrhoidal disease. As a supportive treatment in perirectal abscesses and ...

Synthaverse S.A. resources (1)